Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Influence of Cremophor EL and genetic polymorphisms on the pharmacokinetics of paclitaxel and its metabolites using a mechanism-based model.

Drug metabolism and disposition: the biological fate of chemicals - 1 Feb 2011

Fransson Martin N, Gréen Henrik, Litton Jan-Eric, Friberg Lena E

Abstract excerpt

The formulation vehicle Cremophor EL has previously been shown to affect paclitaxel kinetics, but it is not known whether it also affects the kinetics of paclitaxel metabolites. This information may be important for understanding paclitaxel metabolism in vivo and in the investigation of the role of genetic polymorphisms in the metabolizing enzymes CYP2C8 and CYP3A4/CYP3A5 and the ABCB1 transporter. In this study...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Phytogenic
Share to Biotransformation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemistry, Pharmaceutical

Share to Cytochrome P-450 CYP2C8

Share to Drug Carriers

Share to Genital Neoplasms, Female

Share to Glycerol

Share to Paclitaxel

Source

Identifiers

PMID: 21056987
DOI: 10.1124/dmd.110.035394

Genes

ABCB1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Influence of Cremophor EL and genetic polymorphisms on the pharmacokinetics of paclitaxel and its metabolites using a mechanism-based model.PMID 21056987Read ↗

A pharmacogenetic predictive model for paclitaxel clearance based on the DMET platform.Semantic proximity Read ↗

Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer.Semantic proximity Read ↗

Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel.Semantic proximity Read ↗

Germline pharmacogenetics of paclitaxel for cancer treatment.Semantic proximity Read ↗

Genetic variation in ABCB1 influences paclitaxel pharmacokinetics in Japanese patients with ovarian cancer.Semantic proximity Read ↗

Functional characterization of 12 allelic variants of CYP2C8 by assessment of paclitaxel 6α-hydroxylation and amodiaquine N-deethylation.Semantic proximity Read ↗

Utilization of human liver microsomes to explain individual differences in paclitaxel metabolism by CYP2C8 and CYP3A4.Semantic proximity Read ↗

The Role of CYP2C8 and CYP2C9 Genotypes in Losartan-Dependent Inhibition of Paclitaxel Metabolism in Human Liver Microsomes.Semantic proximity Read ↗

Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer.Semantic proximity Read ↗

Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo.Semantic proximity Read ↗

Relevance of nonsynonymous CYP2C8 polymorphisms to 13-cis retinoic acid and paclitaxel hydroxylation.Semantic proximity Read ↗

CYP2C8 haplotype structures and their influence on pharmacokinetics of paclitaxel in a Japanese population.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.